Published in AIDS Weekly, December 1st, 2003
The program is based on the promising results obtained from proof-of-concept studies with IR103, and is designed to provide data that would support regulatory filings for phase I clinical studies.
IR103 combines Amplivax, an adjuvant being developed by Hybridon, Inc. (HYBN), to enhance the immune response to a vaccine antigen, with the HIV-1 Immunogen technology employed in Remune, an immune-based therapeutic vaccine currently being evaluated in phase II...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.